{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 56,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses two tables to demonstrate competitive advantage in potency and pharmacokinetics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/26",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "ERAS-007 was designed to be a potent, selective, reversible, oral inhibitor of ERK1/2",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16c34443-7808-4d2f-94d4-52cbdea9ec3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "ERAS-007 had longer target residence time vs. other ERKi's, which may allow for longer intervals between doses in patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35d42e7d-513f-43ca-8142-bf73eb36a88f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.507,
        "x": 0.418,
        "y": 0.567
      },
      "kind": "table",
      "text": "Compound: ERAS-007, Ulixertinib, Ravoxertinib. koff: 0.30x10^-4, 10.1x10^-4, 13.9x10^-4. Residence Time: 550, 16, 12.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e88ed39e-5ca0-4edb-9900-793a0223fa05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.507,
        "x": 0.418,
        "y": 0.227
      },
      "kind": "table",
      "text": "Assay Type: Biochemical (ERK1, ERK2), Cell-based mechanistic (HT-29) (pRSK). IC50 values: 2, 2, 7.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa2c05bd-449f-4a7b-8562-23535886ff34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "We believe ERAS-007 is the most potent ERK inhibitor in development, with a uniquely longer target residence time",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a66ce671-e306-4571-9b4e-904d88e5cbd7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "74e86471-804f-4de8-9da8-dd36fb1efdf9",
      "evidence": "The slide presents a table comparing the properties of different ERK inhibitors, which is a clear example of a data table.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 16,
      "beatId": "de59f7d9-38c9-46a9-8877-a3655888462f",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Erasca's pipeline and clinical data",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Slides 16-42 present Erasca's pipeline and clinical data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}